PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: dental hygienist

Public Assessment Report

Public Assessment Report National procedure Vaxzevria (previously COVID-19 Vaccine AstraZeneca, suspension for injection) COVID-19 Vaccine (ChAdOx1-S [recombinant]) PLGB 17901/0355 AstraZeneca UK LimitedVaxzevria (previously COVID-19 Vaccine AstraZeneca), suspension for injection Full dossier, Regulation 50 2 LAY SUMMARY Vaxzevria (previously COVID-19 Vaccine AstraZeneca, suspension for injection) COVID-19 Vaccine (ChAdOx1-S [recombinant]) This is a summary of the Public Assessment Report (PAR) for Vaxzevria (previously COVID-19 Vaccine AstraZeneca, suspension for injection). It explains how this product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product. This product was approved with a national Conditional Marketing Authorisation (CMA) which is used for medicinal products that fulfil an unmet medical need. This product will be referred to as Vaxzevria in this lay summary for ease of reading and by its previous name, COVID 19 Vaccine AstraZeneca, suspension for injection, elsewhere in this PAR.

Adequate evidence of safety and efficacy to enable the MHRA to conclude that the benefits are greater than the risks is required. Any new information on COVID-19 Vaccine AstraZeneca will be reviewed every year and this report will be updated as necessary. In line with the legal requirements for children's medicines, the application included a

Loading..

Tags:

  Safety, Medicine, Children, For children

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of Public Assessment Report

Related search queries